Fosamprenavir Calcium Salt Inhibitor

Solid. Powder

98.00%

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

623.67

DMSO: 1.8mg/mL (2.89mM) Need ultrasonic and warming
H2O: 0.25mg/mL (0.40mM) Need ultrasonic and warming
DMSO: 5mg/mL (28.04mM)
(<1mg/ml refers to the product slightly soluble or insoluble)

C25H34CaN3O9PS

[Ca++].CC(C)CN(C[C@@H](OP([O-])([O-])=O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1

226700-81-8

HIV

Oral gavage of DATS significantly retarded growth of PC-3 xenografts in athymic mice without causing weight loss. For instance, 20 days after starting therapy, the average tumor volume in control mice was approximately 3-fold higher compared with DATS-treated mice. Tumors from DATS-treated mice exhibited a markedly higher count of apoptotic bodies compared with control tumors. Consistent with the results in cultured PC-3 cells, the DATS-mediated suppression of PC-3 xenograft growth correlated with induction of proapoptotic proteins Bax and Bak. Although DATS treatment,inhibited migration of cultured PC-3 cells in association with down-regulation of vascular endothelial growth factor receptor-2 protein, formation of new blood vessels was comparable in tumors of control and DATS-treated mice as judged by CD31 immunostaining[1].

Microbiology/Virology; HIV Protease; Proteases/Proteasome